News summary

Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026

Source: PR Newswire • Published: 16 Nov 2026, 09:10

Summarized by Masters of Longevity from PR Newswire.

Preclinical studies showed potent receptor activity and weight loss in animal models.

Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026
Key Takeaways
  • ASC30_48 FDC showed greater weight loss versus monotherapies in monkeys.
  • ASC48 was a potent GIPR agonist with good oral exposure in NHPs.
  • ASC37 had long half-life and reduced weight in rodent and NHP models.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.